PF-0463481，可口服的 CCR2/5 双重拮抗剂，与玻璃体内治疗相比，具有良好的眼部安全性。PF-0463481 安全且耐受性良好，正在开发用于治疗糖尿病肾病。
CAS：1228111-63-4
分子式：C25H36F3N5O3
分子量：511.58
纯度：98%
存储：Store at -20°C

Background:

PF-0463481, an oral CCR2/5 dual antagonist, with a favorable ocular safety profile versus intravitreal therapies[1]. PF-0463481 is safe and well-tolerated and being developed for the treatment of diabetic nephropathy[2]. CCR2 CCR5

[1]. Gale JD, et al. A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2659-2669. [2]. Gale JD, et al. Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. Kidney Int Rep. 2018 Aug 3;3(6):1316-1327.